These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 32360950)

  • 1. Biosimilars in pediatric rheumatology and their introduction into routine care.
    Aragon Cuevas O; Hedrich CM
    Clin Immunol; 2020 Jul; 216():108447. PubMed ID: 32360950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars in rheumatology.
    Araújo FC; Gonçalves J; Fonseca JE
    Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Era of biosimilars in rheumatology: reshaping the healthcare environment.
    Smolen JS; Goncalves J; Quinn M; Benedetti F; Lee JY
    RMD Open; 2019; 5(1):e000900. PubMed ID: 31245050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.
    Schulze-Koops H; Skapenko A
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv30-iv48. PubMed ID: 28903543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars in rheumatology: understanding the rigor of their development.
    Goel N; Chance K
    Rheumatology (Oxford); 2017 Feb; 56(2):187-197. PubMed ID: 27241704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
    Aladul MI; Fitzpatrick RW; Chapman SR
    BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. US rheumatologists' beliefs and knowledge about biosimilars: a survey.
    Gibofsky A; McCabe D
    Rheumatology (Oxford); 2021 Feb; 60(2):896-901. PubMed ID: 33146388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.
    El Zorkany B; Al Ani N; Al Emadi S; Al Saleh J; Uthman I; El Dershaby Y; Mounir M; Al Moallim H
    Clin Rheumatol; 2018 May; 37(5):1143-1152. PubMed ID: 29411181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of biosimilar candidate drugs in rheumatology: a literature review.
    Araújo F; Cordeiro I; Teixeira F; Gonçalves J; Fonseca JE
    Acta Reumatol Port; 2014; 39(1):19-26. PubMed ID: 24811458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Position paper from the Spanish Society of Rheumatology on biosimilar drugs.
    Abad Hernández MÁ; Andreu JL; Caracuel Ruiz MÁ; Belmonte Serrano MÁ; Díaz-González F; Moreno Muelas JV
    Reumatol Clin; 2015; 11(5):269-78. PubMed ID: 25982595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars in rheumatology: current perspectives and lessons learnt.
    Dörner T; Kay J
    Nat Rev Rheumatol; 2015 Dec; 11(12):713-24. PubMed ID: 26282080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.
    Uhlig T; Goll GL
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv49-iv62. PubMed ID: 28903542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future landscape of biosimilars in rheumatology: Where we are where we are going.
    Scheinberg M; Azevedo V
    Autoimmun Rev; 2019 Feb; 18(2):203-208. PubMed ID: 30572130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The advent of biosimilar therapies in rheumatology--"O brave new world".
    Scheinberg MA; Kay J
    Nat Rev Rheumatol; 2012 Jun; 8(7):430-6. PubMed ID: 22664834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on biosimilars in rheumatology.
    Rischin A; Östör AJ
    Inflammopharmacology; 2017 Apr; 25(2):177-184. PubMed ID: 28265837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea.
    Cho SK; Jung SY; Kim H; Song YJ; Lee K; Sung YK
    J Korean Med Sci; 2021 May; 36(20):e143. PubMed ID: 34032032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
    Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region.
    Rath PD; Chen DY; Gu J; Lee VWY; Al Ani NA; Shirazy K; Llamado L
    Int J Rheum Dis; 2019 Jan; 22(1):9-24. PubMed ID: 30338644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.
    Becciolini A; Raimondo MG; Crotti C; Agape E; Biggioggero M; Favalli EG
    Drug Des Devel Ther; 2017; 11():1969-1978. PubMed ID: 28721016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?
    Azevedo VF; Babini A; Caballero-Uribe CV; Castañeda-Hernández G; Borlenghi C; Jones HE
    J Clin Rheumatol; 2019 Mar; 25(2):91-100. PubMed ID: 30059414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.